Nantahala Capital Partners Limited Partnership

Overview

• HeadquartersNew Canaan, United States²
• Legal formLimited Partnership²
• Kind of organizationHedge fund²
• LEI549300DMVG6YYLMHJ669²
• StatusActive²
• LEI statusIssued and current²
• Registered addressC/O BUSINESS FILINGS INCORPORATED, 02110 Boston, United States²
• Registered withSecurities and Exchange Commission, 0001502725²

See how the biggest companies compare on our leaderboards

Corporate structure

Nantahala Capital Partners Limited Partnership sits at the top of its group. 12 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); stakes of 5% or more it reported on Schedules 13D and 13G (11 companies). Each entity in the chart links to its source.

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Managing Member of the General PartnerDaniel J. Mack named Sep 25, 2026³
• Managing Member of the General PartnerWilmot B. Harkey named Sep 25, 2026³

Subsidiaries and ownership

Fund manager

• Nantahala Capital Management, LLC²

Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record.

Timeline

1. May 24, 2004Founded Nantahala Capital Partners Limited Partnership is founded²

Filings

7 filings to the SEC since October 2021: 7 private raises. The latest 7:

1. Sep 25, 2026D/A EDGAR
2. Sep 25, 2026D EDGAR
3. Sep 29, 2025D/A EDGAR
4. Oct 4, 2024D/A EDGAR
5. Oct 6, 2023D/A EDGAR
6. Oct 7, 2022D/A EDGAR
7. Oct 12, 2021D/A EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Stakes it holds

Nantahala Capital Partners Limited Partnership has told the SEC it owns more than 5% of 11 companies, latest first (Schedules 13D and 13G).

• FEMASYS INCSCHEDULE 13D Aug 17, 2026⁴
• Azitra, Inc.SCHEDULE 13G Aug 14, 2026⁵
• ABEONA THERAPEUTICS INC.SCHEDULE 13G/A Oct 6, 2025 to May 15, 2026⁶
• KIORA PHARMACEUTICALS INCSCHEDULE 13G/A Aug 14, 2025 to May 15, 2026⁷
• CURIS INCSCHEDULE 13G Apr 7, 2026⁸
• DarioHealth Corp.SCHEDULE 13G/A Mar 6, 2025 to Nov 14, 2025⁹
• InspireMD, Inc.SCHEDULE 13G/A Dec 4, 2024 to Nov 14, 2025¹⁰
• Senti Biosciences Holdings, Inc.SCHEDULE 13G/A Feb 14, 2025 to May 15, 2025¹¹
• Surrozen, Inc./DESCHEDULE 13G/A Nov 14, 2024 to May 15, 2025¹²
• EAGLE PHARMACEUTICALS, INC.SCHEDULE 13G Feb 19, 2025¹³
• Unicycive Therapeutics, Inc.SCHEDULE 13G/A Feb 5, 2024 to Dec 20, 2024¹⁴

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Aug 11, 2004Raised $198.3 million in a private offering of securities³ Form D: 126 investors so far Form D
2. Aug 11, 2004Raised $198.3 million in a private offering of securities¹⁵ Form D: 126 investors so far Form D